Alizadeh Sheida, Edalat Fahime, Letafati Arash, Pirbonyeh Neda, Tabibzadeh Alireza, Mousavizadeh Leila, Moattari Afagh, Karbalaie Niya Mohammad Hadi
Department of Virology and Bacteriology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Autophagy Research Center, Shiraz University of Medical Science, Shiraz, Iran.
Virus Genes. 2025 Feb;61(1):54-63. doi: 10.1007/s11262-024-02119-x. Epub 2024 Nov 5.
Influenza virus neuraminidase inhibitors (NAIs) drug usage can result in NAI resistance, especially in children and individuals with weakened immune systems. The aim of the present study was to identify NAI-resistant variants of IBV and to introduce probable novel mutations, phylogenetic study, and its epitope mapping based on NA gene in patients from Shiraz, Iran. A cross-sectional study was conducted between 2017 and 2018 on symptomatic children. A real-time PCR was run for IBV screening. Then, making use of direct sequencing, amplified 1401 bases of NA gene and phylogenetic tree reconstructed. Epitopes were predicted using ABCpred server. From among a total of 235 specimens, 9.7% were identified with IBV infection. Of them, sequence of NA gene for 17 isolates were analyzed. Phylogenetic analysis showed that 15 isolates belonged to Yamagata clade 3 Wisconsin/01-like subclade and 2 were related to Victoria clade 1 Brisbane/60-like subclade (Vic-1A-2). NA gene sequence analysis showed a total of 52 substitutions in which 27 were for B and 37 were for B isolates and 19 were novel substitutions. Only one substitution (S198N) was found in NA active site and T49M, I120V, N198S, N219K, S295R, D320K N340D, E358K, D384G, and D463N were found as probable resistance variants to NAIs. Epitope mapping showed some major differences in our isolates NA gene. Present study was one of the rare comprehensive studies conducted in Shiraz/Iran on IBV resistant associated variants to NAIs. We reported 11.7% mutation in NA active site and some probable NAIs resistant mutations. Epitope mapping confirmed major changes in NA gene which needs broader studies to confirm.
流感病毒神经氨酸酶抑制剂(NAIs)的使用会导致对NAIs产生耐药性,尤其是在儿童和免疫系统较弱的个体中。本研究的目的是鉴定伊朗设拉子患者中IBV的NAIs耐药变异体,并基于NA基因进行可能的新突变分析、系统发育研究及其表位作图。2017年至2018年对有症状儿童进行了一项横断面研究。对IBV进行实时PCR筛查。然后,利用直接测序法扩增NA基因的1401个碱基并重建系统发育树。使用ABCpred服务器预测表位。在总共235个样本中,9.7%被鉴定为感染了IBV。其中,对17株分离株的NA基因序列进行了分析。系统发育分析表明,15株分离株属于山形分支3威斯康星/01样亚分支,2株与维多利亚分支1布里斯班/60样亚分支(Vic-1A-2)相关。NA基因序列分析显示共有52个替换,其中27个是B株的,37个是B分离株的,19个是新替换。在NA活性位点仅发现一个替换(S198N),T49M、I120V、N198S、N219K、S295R、D320K、N340D、E358K、D384G和D463N被发现为可能对NAIs耐药的变异体。表位作图显示我们的分离株NA基因存在一些主要差异。本研究是伊朗设拉子针对与NAIs耐药相关变异体的IBV进行的罕见综合研究之一。我们报告了NA活性位点11.7%的突变以及一些可能的NAIs耐药突变。表位作图证实了NA基因的主要变化,这需要更广泛的研究来证实。